Hubert M. Leufkens
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: April 04, 2025
Transitioning to regulatory harmonisation for medicines: a comparison between Africa and Europe.
Journal: Drug discovery today
Published: March 16, 2025
Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study.
Journal: Frontiers in medicine
Published: November 12, 2024
Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?
Journal: Drug discovery today
Published: October 08, 2024
Globalization in clinical drug development for sickle cell disease.
Journal: American journal of hematology
Published: July 27, 2024
Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: April 30, 2024
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report.
Journal: Clinical pharmacology and therapeutics
Published: January 02, 2024
Successes and pitfalls in orphan drug development for sickle cell disease.
Journal: Blood advances
Published: September 20, 2023
Identifying Medicine Shortages With the Twitter Social Network: Retrospective Observational Study.
Journal: Journal of medical Internet research
Published: August 22, 2023
Traits, trends and hits of orphan drug designations in cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: May 01, 2023
Last Updated: 09/26/2026